Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

The Bedford company announced its acquisition of Evergreen Theragnostics Inc. Tuesday. Lantheus (Nasdaq: LNTH) is paying $250 million upfront in the all-cash transaction, plus up to an additional ...

On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $ ...

Lantheus is paying $250 million upfront to acquire clinical-stage radiopharma CDMO and drug discovery shop Evergreen Theragnostics. As part of the deal, Evergreen and its investors could receive ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...

(RTTNews) - Lantheus Holdings (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics, Inc. in an all-cash transaction consisting of an upfront payment of $250 million and up to ...

Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...

Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...